Chen Hai-fei, Fu Wei-Jun, Wang Dong-Xing, Yuan Zhen-Gang, Chen Yu-Bao, Hou Jian
Department of Hematology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Zhonghua Xue Ye Xue Za Zhi. 2007 Oct;28(10):655-8.
To analyze the clinical and laboratory features and risk factors of multiple myeloma (MM) with extramedullary disease (EM) and its extraosseous localizations at diagnosis and during the course of MM.
The clinical features, survival rate and prognostic factors were retrospectively analyzed in 40 patients having EM from a total of 418 MM patients hospitalized in Changzheng Hospital from 1993 to 2006.
Among the 40 patients, the first three localizations of EM involved soft tissue, pleura or peritoneum and central nervous system (CNS). Median duration of follow-up was 30 months. The median overall survival (OS) was 28 months. Twenty-five patients (6%) were found to have EM at diagnosis (group A), and their median OS was 16 months and 15 patients (3.6%) developed EM during the course of the disease (group B), and their expected median OS was 72 months. There was a significant difference between group A and B (P = 0.0045) for OS. Compared with those in group A, patients in group B had a higher percentage of plasmacytes (P = 0.022) and plasmablasts (P = 0.029) in bone marrow, and less advanced stage for international staging system (ISS) (P = 0.027). Log-rank univariate analysis showed that higher CRP level, higher serum LDH, Stage II and III for ISS, Hb < 110 g/L at diagnosis were poor prognostic factors. However, multivariate analysis with COX model showed none of them were statistically significant.
EM tumors are not a rare manifestation of MM. Soft tissue in the commonest area involved. Higher serum CRP and LDH level, more advanced stage for ISS, anemia and having EM are poor prognostic factors of MM.
分析多发性骨髓瘤(MM)合并髓外疾病(EM)的临床和实验室特征、危险因素及其在MM诊断时和病程中的髓外定位。
回顾性分析1993年至2006年在长征医院住院的418例MM患者中40例合并EM患者的临床特征、生存率和预后因素。
40例患者中,EM的前三个定位部位为软组织、胸膜或腹膜及中枢神经系统(CNS)。中位随访时间为30个月。中位总生存期(OS)为28个月。25例患者(6%)在诊断时发现有EM(A组),其OS中位数为16个月;15例患者(3.6%)在病程中发生EM(B组),其预期OS中位数为72个月。A组和B组的OS有显著差异(P = 0.0045)。与A组相比,B组患者骨髓中的浆细胞百分比(P = 0.022)和原始浆细胞百分比(P = 0.029)更高,国际分期系统(ISS)分期更晚(P = 0.027)。对数秩单因素分析显示,较高的CRP水平、较高的血清LDH、ISS的II期和III期、诊断时Hb < 110 g/L是不良预后因素。然而,COX模型多因素分析显示这些因素均无统计学意义。
EM肿瘤并非MM的罕见表现。软组织是最常受累的部位。较高的血清CRP和LDH水平、ISS分期更晚、贫血以及合并EM是MM的不良预后因素。